m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02978)
Name
VPC-94075
Synonyms
Sphingosine kinase inhibitor (vascular disease); Sphingosine kinase inhibitor (vascular disease), University of Virgina
    Click to Show/Hide
Status
Investigative
Structure
Formula
C15H11ClN2OS
InChI
1S/C15H11ClN2OS/c16-11-3-1-10(2-4-11)14-9-20-15(18-14)17-12-5-7-13(19)8-6-12/h1-9,19H,(H,17,18)
InChIKey
ZFGXZJKLOFCECI-UHFFFAOYSA-N
PubChem CID
753704
TTD Drug ID
D00YNY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Sphingosine kinase 1 (SPHK1)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Sphingosine kinase 1 (SPHK1) is a therapeutic target for VPC-94075. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of VPC-94075 through regulating the expression of Sphingosine kinase 1 (SPHK1). [1], [2]
References
Ref 1 ALKBH5 Regulates SPHK1-Dependent Endothelial Cell Angiogenesis Following Ischemic Stress. Front Cardiovasc Med. 2022 Jan 20;8:817304. doi: 10.3389/fcvm.2021.817304. eCollection 2021.
Ref 2 A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 2008 Aug 15;112(4):1382-91. doi: 10.1182/blood-2008-02-138958. Epub 2008 May 29.